All In Biotech

Drug Trial Radar · NCT06744647

Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation

A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate Efficacy and Safety of ALXN2030 in Adult Patients With Antibody-Mediated Rejection After Kidney Transplantation

Last checked: Nov 20, 2026Latest source record: Aug 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

47

Actual

Start

Mar 7, 2025

Primary completion

Oct 11, 2027

Study completion Nov 7, 2028

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
First posted
Dec 20, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.

Conditions

  • Antibody-Mediated Rejection
  • Kidney Transplantation
  • Biopsy-proven Histologic Scores
  • AMR

Interventions

  • ALXN2030Drug

    ALXN2030 will be administered subcutaneously (SC).

  • PlaceboDrug

    Placebo will be administered SC.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Biopsy-proven histologic resolutionTime frame: Week 52

Locations

51 sites in 8 countries. Site status is shown where the registry gives one.

  • Research Site

    Birmingham, Alabama

  • Research Site

    Scottsdale, Arizona

  • Research Site

    Los Angeles, California

  • Research Site

    Orange, California

  • Research Site

    Tampa, Florida

  • Research Site

    Atlanta, Georgia

  • Research Site

    Kansas City, Kansas

  • Research Site

    Ann Arbor, Michigan

  • Research Site

    Detroit, Michigan

  • Research Site

    Livingston, New Jersey

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    New York, New York

  • Research Site

    Durham, North Carolina

  • Research Site

    Cincinnati, Ohio

  • Research Site

    Philadelphia, Pennsylvania

  • Research Site

    Dallas, Texas

  • Research Site

    Houston, Texas

  • Research Site

    Richmond, Virginia

  • Research Site

    Seattle, Washington

  • Research Site

    Milwaukee, Wisconsin

  • Research Site

    Botucatu, Brazil

  • Research Site

    Campinas, Brazil

  • Research Site

    Porto Alegre, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    São Paulo, Brazil

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Vancouver, British Columbia, Canada

  • Research Site

    London, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Changsha, China

  • Research Site

    Guangzhou, China

  • Research Site

    Nanning, China

  • Research Site

    Shanghai, China

  • Research Site

    Wuhan, China

  • Research Site

    Xi'an, China

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

  • Research Site

    Seoul, South Korea

Showing 40 of 51 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.